Clinical Report: FDA Approves New Treatment for Thyroid Eye Disease

Overview

The FDA has approved veligrotug-vvze (Lumvoa) for thyroid eye disease (TED), applicable to patients regardless of disease activity or duration. The approval follows positive results from the phase 3 THRIVE trials, which demonstrated significant improvements in proptosis and diplopia.

Background

Thyroid eye disease is an autoimmune condition that leads to inflammation and remodeling of tissues around the eyes, causing symptoms such as proptosis and diplopia. Effective treatment options are crucial for managing the disease's impact. The recent approval of Lumvoa is based on findings from the THRIVE trials.

Data Highlights

Key Findings

• FDA approved veligrotug-vvze (Lumvoa) for TED treatment.
• Approval includes patients with both active and chronic disease.
• Phase 3 THRIVE trials showed significant reductions in proptosis and improvements in diplopia.
• Infusion reactions occurred in approximately 9% of patients.
• Common adverse reactions included muscle spasms, headache, and hyperglycemia.
• ViridianCares program offers support for patient access and financial assistance.

Clinical Implications

Healthcare providers should consider Lumvoa as a treatment option for patients with thyroid eye disease, particularly those with active symptoms. Monitoring for potential adverse reactions, especially in patients with preexisting conditions, is essential.

Conclusion

The approval of Lumvoa marks a significant development in the management of thyroid eye disease, providing a new treatment avenue for affected patients.

Related Resources & Content

1. Viridian Therapeutics, Inc., Press Release, 2026 -- FDA Approves New Treatment for Thyroid Eye Disease
2. Ophthalmology Management, 2025 -- FDA Accepts BLA for Veligrotug for Thyroid Eye Disease
3. Ophthalmology Management, 2022 -- RX PERSPECTIVE
4. Ophthalmology Management, 2026 -- A New Era of Targeted Treatment for TED
5. The Journal of Clinical Endocrinology & Metabolism — 2′-O-Galloylhyperin Prevents Tissue Remodeling in Thyroid Eye Disease: Prospects as a Thyrotropin Receptor Antagonist
6. https://academic.oup.com/ejendo/article/185/4/G43/6654384
7. Management of Thyroid Eye Disease: A Consensus Statement by the American Thyroid Association and the European Thyroid Association
8. Efficacy and Safety of Teprotumumab in Thyroid Eye Disease: A Systematic Review and Meta-Analysis - ScienceDirect
9. AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR SUBCUTANEOUS TEPEZZA® IN ADULTS LIVING WITH MODERATE-TO-SEVERE ACTIVE THYROID EYE DISEASE | Amgen Inc.
10. Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment of Thyroid Eye Disease - Viridian Therapeutics, Inc.
11. Lumvoa (veligrotug) Final USPI